NPS Tier 1 vs Tier 2: Differences, Tax Benefits and Which to Choose
Compare NPS Tier 1 vs Tier 2 on withdrawals, tax benefits, contributions, equity limits and suitability to understand which account may fit your needs.
Read FullArchive of all the blogs posted
Showing 12 articles this page
Compare NPS Tier 1 vs Tier 2 on withdrawals, tax benefits, contributions, equity limits and suitability to understand which account may fit your needs.
Read Full
India imports nearly 90% of its crude oil, yet exports diesel worldwide. See how refining scale, Jamnagar and global shortages created this advantage.
Read Full
Why did Nifty IT rally nearly 16% in July 2026? See how earnings, AI revenue, deal wins and global rotation shaped the rebound in Indian IT stocks.
Read Full
Understand NPS withdrawal rules 2026 for normal exit, premature withdrawal, partial withdrawal, lump sum, annuity, tax and corpus limits.
Read Full
SP Group holds 18.37% of Tata Sons and owes ~₹60,000 crore. Fresh talks explore swapping ~7% for listed Tata shares. No deal yet - both sides remain divided on value. Here is the full picture: gross m
Read Full
Indian banks earned over ₹20,000 crore distributing insurance in FY26. HDFC Bank led at ₹6,927 crore. RBI's new mis-selling rules kick in from January 2027. Here is how bancassurance works, what the r
Read Full
FPIs bought ₹15,559 crore in Indian equities in the first fortnight of July 2026 — the second straight fortnight of net buying. Consumer services led at $765M, metals at $623M. Autos saw $721M selling
Read Full
Brent crosses $100, Houthis attack Red Sea tankers, rupee touches ₹97. FCNR(B) hits $20.7bn, Infosys cuts guidance, Nestle profits up 48%. Full weekly breakdown inside.
Read Full
Received a Section 143(1) intimation? Understand CPC adjustments, refunds, tax demands, rectification, revised returns and the correct next step.
Read Full
Brent crossed $100 on July 24, 2026. The rupee hit ₹96.80. India has $675bn in reserves but a $106.6bn RBI forward short. Here is how oil, the rupee, and RBI policy pressure each other and where house
Read Full
India has identified $51 billion of imports across 100 products for domestic manufacturing. Mobile phones show what works. Solar shows what goes wrong. Here is why the 2030 opportunity depends on sequ
Read Full
Over $300 billion in global drug revenue loses exclusivity by 2030. India's generic base is well placed, but the real opportunity lies in complex generics, biosimilars, and API localisation. Here is w
Read Full